Palonosetron (Palonosetron Teva)

Palonosetron

Teva Pharmaceuticals (Pty) Ltd

Registration

Applicant: Teva Pharmaceuticals (Pty) Ltd
Certificate holder: Teva Pharmaceuticals (Pty) Ltd
Registrations: 1

Variants

Product	Strength and form	Registration	Status	Schedule	Leaflets
Palonosetron 0,25 teva Each vial of 5 ml of solution contains PALONOSETRON (AS HYDROCHLORIDE) 0,25 mg	0,25 mgSolution for injection;	49113049/5.10/1130Approved 23 February 2023	Registered	Not determined	PI PIL

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

Listings for this ingredient that could not be applied to this product

S4: Netupitant
Consolidated Schedules 06 July 2026, line 7243
S4: Palonosetron
Consolidated Schedules 06 July 2026, line 7461

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

C₁₉H₂₄N₂O296.40 g/mol

(3AS)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-3a,4,5,6-tetrahydro-3H-benzo[de]isoquinolin-1-one

Drag to rotate. Structure from PubChem CID 6337614.

SAHPRA documents

Professional information (PI)For healthcare professionals Patient information leaflet (PIL)For patients and carers

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Background

Loading Wikipedia summary

Research articles

Loading PubMed articles